ArticleCureus2025
Vaping-Associated Lung Injury With Suspected Diffuse Alveolar Haemorrhage: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
E-cigarette or vaping product use-associated lung injury (EVALI) is a recognised condition with diverse presentations, including acute lung injury and, rarely, diffuse alveolar haemorrhage (DAH). This case report describes a rare instance of suspected DAH associated with herbal-based vape product use, highlighting diagnostic challenges and effective management. A 44-year-old patient with Hashimoto's thyroiditis, asthma and six-week use of herbal or plant-based vaping solutions presented with one week of cough, fever and haemoptysis. Examination revealed respiratory distress, bilateral crackles and wheezing. Arterial blood gas showed type 1 respiratory failure (PaO₂ 10.2 kPa, FiO₂ 0.7), and chest imaging displayed bilateral interstitial opacities suggestive of DAH. Differentials, including pneumonia, pulmonary embolism, vasculitis, Goodpasture's syndrome and malignancy, were evaluated. Bronchoscopy confirmed left upper lobe haemorrhage, with bronchoalveolar lavage showing progressive red blood cells, supporting suspected DAH. Extensive autoimmune, infectious and neoplastic workup (e.g., antinuclear antibody, viral polymerase chain reaction (PCR), cultures) was negative. Empirical antibiotics and antifungals were stopped after negative cultures. On day 3, suspecting DAH, high-dose intravenous methylprednisolone (1,000 mg/day for three days) was initiated for immune-mediated inflammation, yielding rapid clinical and radiological improvement. EVALI with suspected DAH was diagnosed by exclusion post-workup, and vaping cessation was advised. At three months, the patient remained stable without recurrence. This case underscores EVALI as a key differential in vaping patients with haemoptysis and bilateral infiltrates when other aetiologies are excluded. A thorough vaping history, comprehensive workup and prompt corticosteroid therapy can yield favourable outcomes. The rare link between DAH and EVALI warrants further research into its prevalence and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.